Enoxaparin — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Deep Vein Thrombosis

• Apixaban
• Rivaroxaban
• Warfarin

Other medications in Cardiovascular

• Nitroglycerin
• Spironolactone
• Amiodarone
• Aspirin
• Cilostazol
• Clopidogrel
• Dabigatran

About Enoxaparin

Enoxaparin is a vital medication used to prevent and treat dangerous blood clots. For many, its cost can be a significant barrier to consistent treatment. At TheDrugClub, we believe everyone deserves access to life-saving medications. Enoxaparin is a powerful anticoagulant, commonly known by its brand name Lovenox, that plays a critical role in preventing and treating various types of blood clots. These clots can form in blood vessels and, if left untreated, can lead to serious and even life-threatening conditions. ### What Enoxaparin Treats and How It Works

Primarily, enoxaparin is prescribed to prevent deep vein thrombosis (DVT), a condition where blood clots form in deep veins, usually in the legs. These clots can become dangerous if they break loose and travel to the lungs, causing a pulmonary embolism (PE), a medical emergency. Enoxaparin is often used in patients undergoing certain surgeries, particularly hip or knee replacement, or those who are bedridden for extended periods, as these situations increase the risk of clot formation. It's also used to treat existing DVT and PE, and sometimes in patients with unstable angina or certain types of heart attacks. As a low molecular weight heparin, enoxaparin works by thinning the blood. It does this by enhancing the activity of antithrombin, a natural substance in the body that inhibits clotting factors. By reducing the blood's ability to clot, enoxaparin helps prevent new clots from forming and stops existing clots from growing larger, allowing the body to naturally break them down over time. It is administered via subcutaneous injection, usually once or twice daily, as directed by a healthcare professional. ### The Challenge of Cost

For a critical medication like enoxaparin, the cost can be a significant concern. Without insurance, or with a high-deductible plan, a typical prescription can range from hundreds to even thousands of dollars per month, depending on the dosage and quantity. Even with insurance, co-pays can be substantial, creating a financial burden that can lead to missed doses or non-adherence, putting patients at serious risk. Imagine needing this vital medication in [city

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Enoxaparin is approved for (FDA label)

Enoxaparin sodium injection is a low molecular weight heparin [LMWH] indicated for: • Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness ( 1.1 ) • Inpatient treatment of acute DVT with or without pulmonary embolism ( 1.2 ) • Outpatient treatment of acute DVT without pulmonary embolism ( 1.2 ) • Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction [MI] ( 1.3 ) • Treatment of acute ST-segment elevation myocardial infarction [STEMI] managed medically or with subsequent percutaneous coronary intervention [PCI] ( 1.4 ) 1.1 Prophylaxis of Deep Vein Thrombosis Enoxaparin sodium injection is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE): • in patients undergoing abdominal surgery who are at risk for thromboembolic complications [ see Clinical Studies ( 14.1 ) ] • in patients undergoing hip replacement surgery, during and following hospitalization • in patients undergoing knee replacement surgery • in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness 1.2 Treatment of Acute Deep Vein Thrombosis Enoxaparin sodium injection is indicated for: • the inpatient treatment of acute deep vein thrombosis with or without pulmonary embolism, when administered in conjunction with warfarin sodium • the outpatient treatment of acute deep vein thrombosis without pulmonary embolism, when administered in conjunction with warfarin sodium 1.3 Prophylaxis of Ischemic Complications of Unstable Angina and Non-Q-Wave Myocardial Infarction Enoxaparin sodium injection is indicated for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin. 1.4 Treatment of Acute ST-Segment Elevation Myocardial Infarction Enoxaparin sodium injection, when administered concurrently with aspirin, has been shown to reduce the rate of the combined endpoint of recurrent myocardial infarction or death in patients with acute ST-segment elevation myocardial infarction (STEMI) receiving thrombolysis and being managed medically or with percutaneous coronary intervention (PCI).

Source: Read the full FDA label on DailyMed. Label effective date: September 2, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Enoxaparin (FDA label)

WARNING: SPINAL/ EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: • Use of indwelling epidural catheters • Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants • A history of traumatic or repeated epidural or spinal punctures • A history of spinal deformity or spinal surgery • Optimal timing between the administration of enoxaparin sodium injection and neuraxial procedures is not known Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary. Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis [ see Warnings and Precautions ( 5.1 ) and Drug Interactions ( 7 ) ]. WARNING: SPINAL/EPIDURAL HEMATOMAS See full prescribing information for complete boxed warning. Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures.

Source: FDA prescribing information (DailyMed). Set ID: 45a66675-b159-42b8-9f18-ff80f28e1503. SPL document ID: 9baf7028-e55e-42fd-a36b-1c0ddd4421e6. Label effective date: September 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Enoxaparin (FDA label)

Enoxaparin sodium injection, USP is a clear, colorless to pale-yellow sterile solution available in two concentrations. 100 mg/mL Concentration - Single-dose Prefilled Syringes 30 mg/0.3 mL, 40 mg/0.4 mL - Single-dose Graduated Prefilled Syringes 60 mg/0.6 mL, 80 mg/0.8 mL, 100 mg/mL 150 mg/mL Concentration - Single-dose Graduated Prefilled Syringes 120 mg/0.8 mL, 150 mg/mL 100 mg/mL concentration ( 3 ): • Single-dose prefilled syringes: 30 mg/0.3 mL, 40 mg/0.4 mL • Single-dose graduated prefilled syringes: 60 mg/0.6 mL, 80 mg/0.8 mL, 100 mg/mL 150 mg/mL concentration ( 3 ): • Single-dose graduated prefilled syringes: 120 mg/0.8 mL, 150 mg/mL

Source: FDA prescribing information (DailyMed). Set ID: 45a66675-b159-42b8-9f18-ff80f28e1503. SPL document ID: 9baf7028-e55e-42fd-a36b-1c0ddd4421e6. Label effective date: September 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Enoxaparin (FDA label)

The following serious adverse reactions are also discussed in other sections of the labeling: • Spinal/epidural hematomas [ see Boxed Warning and Warnings and Precautions ( 5.1 ) ] • Increased Risk of Hemorrhage [ see Warnings and Precautions ( 5.1 ) ] • Thrombocytopenia [ see Warnings and Precautions ( 5.5 ) ] Most common adverse reactions (>1%) were bleeding, anemia, thrombocytopenia, elevation of serum aminotransferase, diarrhea, nausea, ecchymosis, fever, edema, peripheral edema, dyspnea, confusion, and injection site pain ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC, at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: 45a66675-b159-42b8-9f18-ff80f28e1503. SPL document ID: 9baf7028-e55e-42fd-a36b-1c0ddd4421e6. Label effective date: September 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Enoxaparin (FDA label)

Enoxaparin sodium injection is contraindicated in patients with: • Active major bleeding • History of immune-mediated heparin-induced thrombocytopenia (HIT) within the past 100 days or in the presence of circulating antibodies [see Warnings and Precautions ( 5.4 )] • Known hypersensitivity to enoxaparin sodium ( e.g., pruritus, urticaria, anaphylactic/anaphylactoid reactions) [ see Adverse Reactions ( 6.2 ) ] • Known hypersensitivity to heparin or pork products • Active major bleeding ( 4 ) • History of heparin-induced thrombocytopenia (HIT) within the past 100 days or in the presence of circulating antibodies ( 4 ) • Hypersensitivity to enoxaparin sodium ( 4 ) • Hypersensitivity to heparin or pork products ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 45a66675-b159-42b8-9f18-ff80f28e1503. SPL document ID: 9baf7028-e55e-42fd-a36b-1c0ddd4421e6. Label effective date: September 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Enoxaparin (FDA label)

• Increased Risk of Hemorrhage: Monitor for sign of bleeding ( 5.1 , 5.2 , 5.3 ) • Risk of Heparin-Induced Thrombocytopenia with or without Thrombosis. ( 5.4 ) • Thrombocytopenia: Monitor platelet count closely. ( 5.5 ) • Interchangeability with other heparins: Do not exchange with heparin or other LMWHs ( 5.6 ) • Increased Risk of Thrombosis in Pregnant Women with Mechanical Prosthetic Heart Valves: Women and their fetuses may be at increased risk. Monitor more frequently and adjust dosage as needed. ( 5.7 ) 5.1 Increased Risk of Hemorrhage Cases of epidural or spinal hemorrhage and subsequent hematomas have been reported with the use of enoxaparin sodium injection and epidural or spinal anesthesia/analgesia or spinal puncture procedures, resulting in long-term or permanent paralysis.

Source: FDA prescribing information (DailyMed). Set ID: 45a66675-b159-42b8-9f18-ff80f28e1503. SPL document ID: 9baf7028-e55e-42fd-a36b-1c0ddd4421e6. Label effective date: September 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Enoxaparin (FDA label)

Whenever possible, agents which may enhance the risk of hemorrhage should be discontinued prior to initiation of enoxaparin sodium injection therapy. These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, salicylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone. If coadministration is essential, conduct close clinical and laboratory monitoring [ see Warnings and Precautions ( 5.1 ) ]. Discontinue agents which may enhance hemorrhage risk prior to initiation of enoxaparin sodium injection or conduct close clinical and laboratory monitoring ( 2.6 , 7 )

Source: FDA prescribing information (DailyMed). Set ID: 45a66675-b159-42b8-9f18-ff80f28e1503. SPL document ID: 9baf7028-e55e-42fd-a36b-1c0ddd4421e6. Label effective date: September 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.